KCT0004700招募中未知
Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: A prospective phase II exploratory trial (POHIM_RT trial)
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 70(Year)（—）
- 性别
- Female
入选标准
- •1) histological confirmed cervical cancer
- •2) radical hysterectomy and pelvic lymph node dissection was done
- •3) indicated as below in pathology (more than one)
- •- tumor size =4cm
- •- lymphovascular invasion
- •- cervical stromal invasion =1/2
- •4) age 20-70
- •5) ECOG 0-1
- •6) granulocyte =1.0 x 103/µl, platelet =30 x 103/µl, hemoglobin =10 g/dl
- •7) If the patient voluntarily completes the consent form
排除标准
- •1) pelvic lymph node metastasis
- •2) distant metastiss (retroperitoneal lymph node metastasis)
- •3) resection margin positive
- •4) parametrial invasion
- •5) previous pelvic radiohterapy
- •6 more than 3 months after radical hysterectomy
- •7 serious acute illness
- •8 neoadjuvant chemotherapy
- •9 other cancer history except for thyroid cancer, skin cancer, cervix is situ
研究者
相似试验
招募中
不适用
Postoperative hypofractionated intensity-modulated radiotherapy endometrial cancerKCT0008050Samsung Medical Center92
招募中
不适用
Postoperative intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer trialKCT0004702Samsung Medical Center84
招募中
2 期
Postoperative hypofractionation and simultaneous integrated boost with or without regional nodal irradiation by TomoTherapy for breast cancerBreast cancer patients after breast conserving surgery with or without adjuvant chemotherapyhypofractionationsimultaneous integrated boostTomoTherapybreast cancerTCTR20210623004/A48
尚未招募
Unknown
Comparing Conventional and Hypofractionated Radiation Therapy with Chemotherapy After Cervical Cancer Surgery: A Prospective Multicenter Phase 3 StudyNeoplasmsKCT0009607Samsung Medical Center284
已完成
2 期
Phase II study of hypofractionated postoperative intensity-modulated radiotherapy for prostate cancer in adjuvant and salvage settingsProstate cancerJPRN-UMIN000035287The University of Tokyo55